Mammography

Last updated

Mammography
Mammogram.jpg
Mammography
Other namesMastography
ICD-10-PCS BH0
ICD-9-CM 87.37
MeSH D008327
OPS-301 code 3–10
MedlinePlus 003380

Mammography (also called mastography: DICOM modality = MG) is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast for diagnosis and screening. The goal of mammography is the early detection of breast cancer, typically through detection of characteristic masses or microcalcifications.

Contents

As with all X-rays, mammograms use doses of ionizing radiation to create images. These images are then analyzed for abnormal findings. It is usual to employ lower-energy X-rays, typically Mo (K-shell X-ray energies of 17.5 and 19.6 keV) and Rh (20.2 and 22.7 keV) than those used for radiography of bones. Mammography may be 2D or 3D (tomosynthesis), depending on the available equipment or purpose of the examination. Ultrasound, ductography, positron emission mammography (PEM), and magnetic resonance imaging (MRI) are adjuncts to mammography. Ultrasound is typically used for further evaluation of masses found on mammography or palpable masses that may or may not be seen on mammograms. Ductograms are still used in some institutions for evaluation of bloody nipple discharge when the mammogram is non-diagnostic. MRI can be useful for the screening of high-risk patients, for further evaluation of questionable findings or symptoms, as well as for pre-surgical evaluation of patients with known breast cancer, in order to detect additional lesions that might change the surgical approach (for example, from breast-conserving lumpectomy to mastectomy).

In 2023, the U.S. Preventive Services Task Force issued a draft recommendation statement that all women should receive a screening mammography every two years from age 40 to 74. [1] [2] The American College of Radiology and American Cancer Society recommend yearly screening mammography starting at age 40. [3] The Canadian Task Force on Preventive Health Care (2012) and the European Cancer Observatory (2011) recommend mammography every 2 to 3 years between ages 50 and 69. [4] [5] These task force reports point out that in addition to unnecessary surgery and anxiety, the risks of more frequent mammograms include a small but significant increase in breast cancer induced by radiation. [6] [7] Additionally, mammograms should not be performed with increased frequency in patients undergoing breast surgery, including breast enlargement, mastopexy, and breast reduction. [8]

Types

Digital

Digital mammography is a specialized form of mammography that uses digital receptors and computers instead of X-ray film to help examine breast tissue for breast cancer. [9] The electrical signals can be read on computer screens, permitting more manipulation of images to allow radiologists to view the results more clearly . [9] [10] Digital mammography may be "spot view", for breast biopsy, [11] or "full field" (FFDM) for screening. [9]

Digital mammography is also utilized in stereotactic biopsy. Breast biopsy may also be performed using a different modality, such as ultrasound or magnetic resonance imaging (MRI).

While radiologists [12] had hoped for more marked improvement, the effectiveness of digital mammography was found comparable to traditional X-ray methods in 2004, though there may be reduced radiation with the technique and it may lead to fewer retests. [9] Specifically, it performs no better than film for post-menopausal women, who represent more than three-quarters of women with breast cancer. [13] The U.S. Preventive Services Task Force concluded that there was insufficient evidence to recommend for or against digital mammography. [14]

Digital mammography is a NASA spin-off, utilizing technology developed for the Hubble Space Telescope. [15] As of 2007, about 8% of American screening centers used digital mammography. Around the globe, systems by Fujifilm Corporation are the most widely used.[ citation needed ] In the United States, GE's digital imaging units typically cost US$300,000 to $500,000, far more than film-based imaging systems. [13] Costs may decline as GE begins to compete with the less expensive Fuji systems. [13]

3D mammography

Three-dimensional mammography, also known as digital breast tomosynthesis (DBT), tomosynthesis, and 3D breast imaging, is a mammogram technology that creates a 3D image of the breast using X-rays. When used in addition to usual mammography, it results in more positive tests. [16] Cost effectiveness is unclear as of 2016. [17] Another concern is that it more than doubles the radiation exposure. [18]

Photon counting

Photon-counting mammography was introduced commercially in 2003 and was shown to reduce the X-ray dose to the patient by approximately 40% compared to conventional methods while maintaining image quality at an equal or higher level. [19] The technology was subsequently developed to enable spectral imaging with the possibility to further improve image quality, to distinguish between different tissue types, [20] and to measure breast density. [21] [22]

Galactography

A galactography (or breast ductography) is a now infrequently used type of mammography used to visualize the milk ducts. Prior to the mammography itself, a radiopaque substance is injected into the duct system. This test is indicated when nipple discharge exists.

Medical uses

Normal (left) versus cancerous (right) mammography image Mammo breast cancer.jpg
Normal (left) versus cancerous (right) mammography image

Mammography can detect cancer early when it’s most treatable and can be treated less invasively (thereby helping to preserve quality of life).

According to National Cancer Institute data, since mammography screening became widespread in the mid-1980s, the U.S. breast cancer death rate, unchanged for the previous 50 years, has dropped well over 30 percent. [23] In European countries like Denmark and Sweden, where mammography screening programs are more organized, the breast cancer death rate has been cut almost in half over the last 20 years.[ as of? ]

Mammography screening cuts the risk of dying from breast cancer nearly in half. [24] A recent study published in Cancer showed that more than 70 percent of the women who died from breast cancer in their 40s at major Harvard teaching hospitals were among the 20 percent of women who were not being screened. [25] [ unreliable medical source ] Some scientific studies[ citation needed ] have shown that the most lives are saved by screening beginning at age 40.

A recent study in the British Medical Journal shows that early detection of breast cancer – as with mammography – significantly improves breast cancer survival. [26]

The benefits of mammography screening at decreasing breast cancer mortality in randomized trials are not found in observational studies performed long after implementation of breast cancer screening programs (for instance, Bleyer et al. [27] )

When to start screening

In 2014, the Surveillance, Epidemiology, and End Results Program of the National Institutes of Health reported the occurrence rates of breast cancer based on 1000 women in different age groups. [28] In the 40–44 age group, the incidence was 1.5 and in the 45–49 age group, the incidence was 2.3. [28] In the older age groups, the incidence was 2.7 in the 50–54 age group and 3.2 in the 55–59 age group. [28]

While screening between ages 40 and 50 is somewhat controversial, the preponderance of the evidence indicates that there is a benefit in terms of early detection. Currently, the American Cancer Society, the American Congress of Obstetricians and Gynecologists (ACOG), the American College of Radiology, and the Society of Breast Imaging encourage annual mammograms beginning at age 40. [29] [30] [31]

The National Cancer Institute encourages mammograms every one to two years for women ages 40 to 49. [32] In 2023, United States Preventive Services Task Force (USPSTF) revised the recommendation that women and transgender men undergo biennial mammograms starting at the age of 40, rather than the previously suggested age of 50. [33] This adjustment is prompted by the increasing incidence of breast cancer in the 40 to 49 age group over the past decade.

In contrast, the American College of Physicians, a large internal medicine group, has recently encouraged individualized screening plans as opposed to wholesale biannual screening of women aged 40 to 49. [34] The American Cancer Society recommendations for women at average risk for breast cancer is a yearly mammogram from age 45 to 54 with an optional yearly mammogram from age 40 to 44. [35]

Screening for high-risk population

Women who are at high risk for early-onset breast cancer have separate recommendations for screening. These include those who:

The American College of Radiology recommends these individuals to get annual mammography starting at the age of 30. Those with a history of chest radiation therapy before age 30 should start annually at age 25 of 8 years after their latest therapy (whichever is latest). [37] The American Cancer Society also recommends women at high risk should get a mammogram and breast MRI every year beginning at age 30 or an age recommended by their healthcare provider. [35]

The National Comprehensive Cancer Network (NCCN) advocates screening for women who possess a BRCA1 or BRCA2 mutation or have a first-degree relative with such a mutation, even in the absence of the patient being tested for BRCA1/2 mutations. For women at high risk, NCCN recommends undergoing an annual mammogram and breast MRI between the ages of 25 and 40, considering the specific gene mutation type or the youngest age of breast cancer occurrence in the family. Additionally, NCCN suggests that high-risk women undergo clinical breast exams every 6 to 12 months starting at age 25. These individuals should also engage in discussions with healthcare providers to assess the advantages and disadvantages of 3D mammography and acquire knowledge on detecting changes in their breasts. [38]

Adverse effects

Radiation

The radiation exposure associated with mammography is a potential risk of screening, which appears to be greater in younger women. In scans where women receive 0.25–20 Gray (Gy) of radiation, they have more of an elevated risk of developing breast cancer. [39] A study of radiation risk from mammography concluded that for women 40 years of age and older, the risk of radiation-induced breast cancer was minuscule, particularly compared with the potential benefit of mammographic screening, with a benefit-to-risk ratio of 48.5 lives saved for each life lost due to radiation exposure. [40] This also correlates to a decrease in breast cancer mortality rates by 24%. [39]

Pain

The mammography procedure can be painful. Reported pain rates range from 6–76%, with 23–95% experiencing pain or discomfort. [41] Experiencing pain is a significant predictor in women not re-attending screening. [42] There are few proven interventions to reduce pain in mammography, but evidence suggests that giving women information about the mammography procedure prior to it taking place may reduce the pain and discomfort experienced. [43] Furthermore, research has found that standardised compression levels can help to reduce patients' pain while still allowing for optimal diagnostic images to be produced. [44]

Procedure

Illustration of a mammogram Blausen 0628 Mammogram.png
Illustration of a mammogram
A mobile mammography unit in New Zealand BreastScreen Aotearoa.JPG
A mobile mammography unit in New Zealand

During the procedure, the breast is compressed using a dedicated mammography unit. Parallel-plate compression evens out the thickness of breast tissue to increase image quality by reducing the thickness of tissue that X-rays must penetrate, decreasing the amount of scattered radiation (scatter degrades image quality), reducing the required radiation dose, and holding the breast still (preventing motion blur). In screening mammography, both head-to-foot (craniocaudal, CC) view and angled side-view (mediolateral oblique, MLO) images of the breast are taken. Diagnostic mammography may include these and other views, including geometrically magnified and spot-compressed views of the particular area of concern.[ citation needed ] Deodorant [ citation needed ], talcum powder [45] or lotion may show up on the X-ray as calcium spots, so women are discouraged from applying them on the day of their exam. There are two types of mammogram studies: screening mammograms and diagnostic mammograms. Screening mammograms, consisting of four standard X-ray images, are performed yearly on patients who present with no symptoms. Diagnostic mammograms are reserved for patients with breast symptoms (such as palpable lumps, breast pain, skin changes, nipple changes, or nipple discharge), as follow-up for probably benign findings (coded BI-RADS 3), or for further evaluation of abnormal findings seen on their screening mammograms. Diagnostic mammograms may also performed on patients with personal or family histories of breast cancer. Patients with breast implants and other stable benign surgical histories generally do not require diagnostic mammograms.

Until some years ago, mammography was typically performed with screen-film cassettes. Today, mammography is undergoing transition to digital detectors, known as digital mammography or Full Field Digital Mammography (FFDM). The first FFDM system was approved by the FDA in the U.S. in 2000. This progress is occurring some years later than in general radiology. This is due to several factors:

  1. The higher spatial resolution demands of mammography
  2. Significantly increased expense of the equipment
  3. Concern by the FDA that digital mammography equipment demonstrate that it is at least as good as screen-film mammography at detecting breast cancers without increasing dose or the number of women recalled for further evaluation.

As of March 1, 2010, 62% of facilities in the United States and its territories have at least one FFDM unit. [46] (The FDA includes computed radiography units in this figure. [47] )

Tomosynthesis, otherwise known as 3D mammography, was first introduced in clinical trials in 2008 and has been Medicare-approved in the United States since 2015. As of 2023, 3D mammography has become widely available in the US and has been shown to have improved sensitivity and specificity over 2D mammography.

Mammograms are either looked at by one (single reading) or two (double reading) trained professionals: [48] these film readers are generally radiologists, but may also be radiographers, radiotherapists, or breast clinicians (non-radiologist physicians specializing in breast disease). [48]

Double reading significantly improves the sensitivity and specificity of the procedure, and is standard practice in the United Kingdom, but not in the United States as it is not reimbursed by Medicare or private health insurance. This is despite multiple trials showing increased accuracy of detection and improved patient outcomes for both morbidity and mortality when double reading is employed. [48] Clinical decision support systems may be used with digital mammography (or digitized images from analogue mammography [49] ), but studies suggest these approaches do not significantly improve performance or provide only a small improvement. [48] [50]

Interpretation of results

BI-RADS

Stratification for breast cancer risk on a mammogram is based on a reporting system known as BI-RADS, developed by the American College of Radiology in 1993. It has five general categories of findings: mass, asymmetry, architectural distortion, calcifications, and associated features.

The use of language with BI-RADS is extremely precise, with a limited set of permissible adjectives for lesion margins, shape and internal density, each of which carries a different prognostic significance. Margins of a lesion, for example, can only be described as circumscribed, obscured, micropapillary, indistinct or stellate. Similarly, shape can only be round, oval or irregular. Each of these agreed upon adjectives is referred to as a "descriptor" in the BI-RADS lexicon, with specific positive and negative predictive values for breast cancer with each word. This fastiduous attention to semantics with BI-RADS allows for standardization of cancer detection across different treatment centers and imaging modalities. [51]

After describing the findings, the radiologist provides a final assessment ranging from 0 to 6:

  • BI-RADS 0 indicates an incomplete assessment which needs additional imaging.
  • BI-RADS 1 & 2 indicate a negative and benign screen mammogram respectively.
  • BI-RADS 3 indicates probably benign. [52]
  • BI-RADS 4 indicates suspicious for malginancy.
  • BI-RADS 5 indicates highly suggestive of malignancy.
  • BI-RADS 6 is for biopsy-proven breast cancer. [53]

BI-RADS 3, 4 and 5 assessments on screening mammograms require further investigation with a second "diagnostic" study. The latter is a more detailed mammogram that allows dedicated attention to the abnormal finding with additional maneuvers such as magnification, rolling of breast tissue or exaggerated positioning. There may also be imaging with ultrasound at this time, which carries its own parallel BI-RADS lexicon. Suspicious lesions are then biopsied with local anesthesia or proceed straight to surgery depending on their staging. [54] Biopsy can be done with the help of x-rays or ultrasound, depending on which imaging modality shows the lesion best. [55]

In the UK mammograms are scored on a scale from 1–5 (1 = normal, 2 = benign, 3 = indeterminate, 4 = suspicious of malignancy, 5 = malignant). Evidence suggests that accounting for genetic risk, factors improve breast cancer risk prediction. [56]

History

As a medical procedure that induces ionizing radiation, the origin of mammography can be traced to the discovery of X-rays by Wilhelm Röntgen in 1895.

In 1913, German surgeon Albert Salomon performed a mammography study on 3,000 mastectomies, comparing X-rays of the breasts to the actual removed tissue, observing specifically microcalcifications. [57] [58] By doing so, he was able to establish the difference as seen on an X-ray image between cancerous and non-cancerous tumors in the breast. [58] Salomon's mammographs provided substantial information about the spread of tumors and their borders. [59]

In 1930, American physician and radiologist Stafford L. Warren published "A Roentgenologic Study of the Breast", [60] a study where he produced stereoscopic X-rays images to track changes in breast tissue as a result of pregnancy and mastitis. [61] [62] In 119 women who subsequently underwent surgery, he correctly found breast cancer in 54 out of 58 cases. [61]

As early as 1937, Jacob Gershon-Cohen developed a form a mammography for a diagnostic of breast cancer at earlier stages to improve survival rates. [63] In 1949, Raul Leborgne sparked renewed enthusiasm for mammography by emphasizing the importance of technical proficiency in patient positioning and the adoption of specific radiological parameters. He played a pioneering role in elevating imaging quality while placing particular emphasis on distinguishing between benign and malignant calcifications. [64] In the early 1950s, Uruguayan radiologist Raul Leborgne developed the breast compression technique to produce better quality images, and described the differences between benign and malign microcalcifications. [65]

In 1956, Gershon-Cohen conducted clinical trails on over 1,000 asymptomatic women at the Albert Einstein Medical Center on his screening technique, [63] and the same year, Robert Egan at the University of Texas M.D. Anderson Cancer Center combined a technique of low kVp with high mA and single emulsion films developed by Kodak to devise a method of screening mammography. He published these results in 1959 in a paper, subsequently vulgarized in a 1964 book called Mammography. [66] The "Egan technique", as it became known, enabled physicians to detect calcification in breast tissue; [67] of the 245 breast cancers that were confirmed by biopsy among 1,000 patients, Egan and his colleagues at M.D. Anderson were able to identify 238 cases by using his method, 19 of which were in patients whose physical examinations had revealed no breast pathology.

Use of mammography as a screening technique spread clinically after a 1966 study demonstrating the impact of mammograms on mortality and treatment led by Philip Strax. This study, based in New York, was the first large-scale randomized controlled trial of mammography screening. [68] [69]

In 1985, László Tabár and colleagues documented findings from mammographic screening involving 134,867 women aged 40 to 79. Using a single mediolateral oblique image, they reported a 31% reduction in mortality. [64] Dr. Tabár has since written many publications promoting mammography in the areas of epidemiology, screening, early diagnosis, and clinical-radiological-pathological correlation.

Arguments against screening mammography

The use of mammography as a screening tool for the detection of early breast cancer in otherwise healthy women without symptoms is seen by some as controversial. [70] [71] [72]

Keen and Keen indicated that repeated mammography starting at age fifty saves about 1.8 lives over 15 years for every 1,000 women screened. [73] This result has to be seen against the adverse effects of errors in diagnosis, over-treatment, and radiation exposure.

The Cochrane analysis of screening indicates that it is "not clear whether screening does more good than harm". According to their analysis, 1 in 2,000 women will have her life prolonged by 10 years of screening, while 10 healthy women will undergo unnecessary breast cancer treatment. Additionally, 200 women will experience significant psychological stress due to false positive results. [74]

The Cochrane Collaboration (2013) concluded after ten years that trials with adequate randomization did not find an effect of mammography screening on total cancer mortality, including breast cancer. The authors of this Cochrane review write: "If we assume that screening reduces breast cancer mortality by 15% and that overdiagnosis and over-treatment is at 30%, it means that for every 2,000 women invited for screening throughout 10 years, one will avoid dying of breast cancer and 10 healthy women, who would not have been diagnosed if there had not been screening, will be treated unnecessarily. Furthermore, more than 200 women will experience important psychological distress including anxiety and uncertainty for years because of false positive findings." The authors conclude that the time has come to re-assess whether universal mammography screening should be recommended for any age group. [74] They state that universal screening may not be reasonable. [75] The Nordic Cochrane Collection updated research in 2012 and stated that advances in diagnosis and treatment make mammography screening less effective today, rendering it "no longer effective". They conclude that "it therefore no longer seems reasonable to attend" for breast cancer screening at any age, and warn of misleading information on the internet. [75]

Newman posits that screening mammography does not reduce death overall, but causes significant harm by inflicting cancer scare and unnecessary surgical interventions. [76] The Nordic Cochrane Collection notes that advances in diagnosis and treatment of breast cancer may make breast cancer screening no longer effective in decreasing death from breast cancer, and therefore no longer recommend routine screening for healthy women as the risks might outweigh the benefits. [75]

Of every 1,000 U.S. women who are screened, about 7% will be called back for a diagnostic session (although some studies estimate the number to be closer to 10% to 15%). [77] About 10% of those who are called back will be referred for a biopsy. Of the 10% referred for biopsy, about 3.5% will have cancer and 6.5% will not. Of the 3.5% who have cancer, about 2 will have an early stage cancer that will be cured after treatment.

Mammography may also produce false negatives. Estimates of the numbers of cancers missed by mammography are usually around 20%. [78] Reasons for not seeing the cancer include observer error, but more frequently it is because the cancer is hidden by other dense tissue in the breast, and even after retrospective review of the mammogram the cancer cannot be seen. Furthermore, one form of breast cancer, lobular cancer, has a growth pattern that produces shadows on the mammogram that are indistinguishable from normal breast tissue.

Mortality

The Cochrane Collaboration states that the best quality evidence does not demonstrate a reduction in mortality or a reduction in mortality from all types of cancer from screening mammography. [74]

The Canadian Task Force found that for women ages 50 to 69, screening 720 women once every 2 to 3 years for 11 years would prevent one death from breast cancer. For women ages 40 to 49, 2,100 women would need to be screened at the same frequency and period to prevent a single death from breast cancer. [4]

Women whose breast cancer was detected by screening mammography before the appearance of a lump or other symptoms commonly assume that the mammogram "saved their lives". [79] In practice, the vast majority of these women received no practical benefit from the mammogram. There are four categories of cancers found by mammography:

  1. Cancers that are so easily treated that a later detection would have produced the same rate of cure (women would have lived even without mammography).
  2. Cancers so aggressive that even early detection is too late to benefit the patient (women who die despite detection by mammography).
  3. Cancers that would have receded on their own or are so slow-growing that the woman would die of other causes before the cancer produced symptoms (mammography results in over-diagnosis and over-treatment of this class).
  4. A small number of breast cancers that are detected by screening mammography and whose treatment outcome improves as a result of earlier detection.

Only 3% to 13% of breast cancers detected by screening mammography will fall into this last category. Clinical trial data suggests that 1 woman per 1,000 healthy women screened over 10 years falls into this category. [79] Screening mammography produces no benefit to any of the remaining 87% to 97% of women. [79] The probability of a woman falling into any of the above four categories varies with age. [80] [81]

A 2016 review for the United States Preventive Services Task Force found that mammography was associated with an 8%-33% decrease in breast cancer mortality in different age groups, but that this decrease was not statistically significant at the age groups of 39–49 and 70–74. The same review found that mammography significantly decreased the risk of advanced cancer among women aged 50 and older by 38%, but among those aged 39 to 49 the risk reduction was a non-significant 2%. [82] The USPSTF made their review based on data from randomized controlled trials (RCT) studying breast cancer in women between the ages of 40-49. [28]

False positives

The goal of any screening procedure is to examine a large population of patients and find the small number most likely to have a serious condition. These patients are then referred for further, usually more invasive, testing. Thus a screening exam is not intended to be definitive; rather it is intended to have sufficient sensitivity to detect a useful proportion of cancers. The cost of higher sensitivity is a larger number of results that would be regarded as suspicious in patients without disease. This is true of mammography. The patients without disease who are called back for further testing from a screening session (about 7%) are sometimes referred to as "false positives". There is a trade-off between the number of patients with disease found and the much larger number of patients without disease that must be re-screened.[ citation needed ]

Research shows [83] that false-positive mammograms may affect women's well-being and behavior. Some women who receive false-positive results may be more likely to return for routine screening or perform breast self-examinations more frequently. However, some women who receive false-positive results become anxious, worried, and distressed about the possibility of having breast cancer, feelings that can last for many years.[ citation needed ]

False positives also mean greater expense, both for the individual and for the screening program. Since follow-up screening is typically much more expensive than initial screening, more false positives (that must receive follow-up) means that fewer women may be screened for a given amount of money. Thus as sensitivity increases, a screening program will cost more or be confined to screening a smaller number of women.[ citation needed ]

Overdiagnosis

The central harm of mammographic breast cancer screening is overdiagnosis: the detection of abnormalities that meet the pathologic definition of cancer but will never progress to cause symptoms or death. Dr. H. Gilbert Welch, a researcher at Dartmouth College, states that "screen-detected breast and prostate cancer survivors are more likely to have been over-diagnosed than actually helped by the test." [79] Estimates of overdiagnosis associated with mammography have ranged from 1% to 54%. [84] In 2009, Peter C. Gotzsche and Karsten Juhl Jørgensen reviewed the literature and found that 1 in 3 cases of breast cancer detected in a population offered mammographic screening is over-diagnosed. [85] In contrast, a 2012 panel convened by the national cancer director for England and Cancer Research UK concluded that 1 in 5 cases of breast cancer diagnosed among women who have undergone breast cancer screening are over-diagnosed. This means an over-diagnosis rate of 129 women per 10,000 invited to screening. [86] A recent systematic review of 30 studies found that screening mammography for breast cancer among women aged 40 years and older was 12.6%. [87]

False negatives

Mammograms also have a rate of missed tumors, or "false negatives". Accurate data regarding the number of false negatives are very difficult to obtain because mastectomies cannot be performed on every woman who has had a mammogram to determine the false negative rate. Estimates of the false negative rate depend on close follow-up of a large number of patients for many years. This is difficult in practice because many women do not return for regular mammography making it impossible to know if they ever developed a cancer. In his book The Politics of Cancer, Dr. Samuel S. Epstein claims that in women ages 40 to 49, one in four cancers are missed at each mammography. Researchers have found that breast tissue is denser among younger women, making it difficult to detect tumors. For this reason, false negatives are twice as likely to occur in pre-menopausal mammograms (Prate). This is why the screening program in the UK does not start calling women for screening mammograms until age 50. [88]

The importance of these missed cancers is not clear, particularly if the woman is getting yearly mammograms. Research on a closely related situation has shown that small cancers that are not acted upon immediately, but are observed over periods of several years, will have good outcomes. A group of 3,184 women had mammograms that were formally classified as "probably benign". This classification is for patients who are not clearly normal but have some area of minor concern. This results not in the patient being biopsied, but rather in having early follow up mammography every six months for three years to determine whether there has been any change in status. Of these 3,184 women, 17 (0.5%) did have cancers. Most importantly, when the diagnosis was finally made, they were all still stage 0 or 1, the earliest stages. Five years after treatment, none of these 17 women had evidence of re-occurrence. Thus, small early cancers, even though not acted on immediately, were still reliably curable. [89]

Cost-effectiveness

Breast cancer imposes a significant economic strain on communities, with the expense of treating stages three and four in the United States in 2017 amounting to approximately $127,000. [90] While early diagnosis and screening methods are important in reducing the death rates, the cost-benefit of breast cancer screening using mammography has been unclear. A recent systematic review of three studies held in Spain, Denmark, and the United States from 2000-2019 found that digital mammography is not cost-beneficial for the healthcare system when compared to other screening methods. Therefore, increasing its frequency may cause higher costs on the healthcare system. While there may be a lack of evidence, it is suggested that digital mammography be performed every two years for ages over 50. [91]

Arguments against the USPSTF recommendations

As the USPSTF recommendations are so influential, changing mammography screenings from 50 to 40 years of age has significant implications to public health. The major concerns regarding this update is whether breast cancer mortality has truly been increasing and if there is new evidence that the benefits of mammography are increasing. [92]

According to National Vital Statistics System, mortality from breast cancer has been steadily decreasing in the United States from 2018 to 2021. There have also been no new randomized trials of screening mammography for women in their 40s since the previous USPSTF recommendation was made. In addition, the 8 most recent randomized trials for this age group revealed no significant effect. [93] Instead, the USPSTF used statistical models to estimate what would happen if the starting age were lowered, assuming that screening mammography reduces breast cancer mortality by 25%. This found that screening 1,000 women from 40–74 years of age, instead of 50-74, would cause 1-2 fewer breast cancer deaths per 1,000 women screened over a lifetime. [94]

Approximately 75 percent of women diagnosed with breast cancer have no family history of breast cancer or other factors that put them at high risk for developing the disease (so screening only high-risk women misses majority of cancers). An analysis by Hendrick and Helvie, [95] published in the American Journal of Roentgenology , showed that if USPSTF breast cancer screening guidelines were followed, approximately 6,500 additional women each year in the U.S. would die from breast cancer.

The largest (Hellquist et al) [96] and longest running (Tabar et al) [97] breast cancer screening studies in history re-confirmed that regular mammography screening cut breast cancer deaths by roughly a third in all women ages 40 and over (including women ages 40–49). This renders the USPSTF calculations off by half. They used a 15% mortality reduction to calculate how many women needed to be invited to be screened to save a life. With the now re-confirmed 29% (or up) figure, the number to be screened using the USPSTF formula is half of their estimate and well within what they considered acceptable by their formula.

Society and culture

Attendance

Many factors affect how many people attend breast cancer screenings. For example, people from minority ethnic communities are also less likely to attend cancer screening. In the UK, women of South Asian heritage are the least likely to attend breast cancer screening. Research is still needed to identify specific barriers for the different South Asian communities. For example, a study showed that British-Pakistani women faced cultural and language barriers and were not aware that breast screening takes place in a female-only environment. [98] [99] [100]

People with mental illnesses are also less likely to attend cancer screening appointments. [101] [102] In Northern Ireland women with mental health problems were shown to be less likely to attend screening for breast cancer, than women without. The lower attendance numbers remained the same even when marital status and social deprivation were taken into account. [103] [104]

Regulation

Mammography facilities in the United States and its territories (including military bases) are subject to the Mammography Quality Standards Act (MQSA). The act requires annual inspections and accreditation every three years through an FDA-approved body. Facilities found deficient during the inspection or accreditation process can be barred from performing mammograms until corrective action has been verified or, in extreme cases, can be required to notify past patients that their exams were sub-standard and should not be relied upon. [105]

At this time,[ when? ] MQSA applies only to traditional mammography and not to related scans, such as breast ultrasound, stereotactic breast biopsy, or breast MRI.

As of September 10, 2024, the MQSA requires that all patients be notified of their breast density ("dense" or "not dense") in their mammogram reports. [106] [107]

Research

Artificial intelligence (AI) algorithms

Recently, artificial intelligence (AI) programs have been developed to utilize features from screening mammography images to predict breast cancer risk. A systematic review of 16 retrospective study designs comparing median maximum AUC found that artificial intelligence had a comparable or better accuracy (AUC = 0.72) of predicting breast cancer than clinical risk factors alone (AUC = 0.61), suggesting a transition from clinical risk factor-based to AI image-based risk models may lead to more accurate and personalized risk-based screening approaches. [108]

Another study of 32 published papers involving 23,804 mammograms and various machine learning methods (CNN, ANN, and SVM) found promising results in the ability to assist clinicians in large-scale population-based breast cancer screening programs. [109]

Alternative examination methods

For patients who do not want to undergo mammography, MRI and also breast computed tomography (also called breast CT) offer a painless alternative. Whether the respective method is suitable depends on the clinical picture; it is decided by the physician.[ citation needed ]

See also

Related Research Articles

<span class="mw-page-title-main">Breast cancer</span> Cancer that originates in mammary glands

Breast cancer is a cancer that develops from breast tissue. Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, milk rejection, fluid coming from the nipple, a newly inverted nipple, or a red or scaly patch of skin. In those with distant spread of the disease, there may be bone pain, swollen lymph nodes, shortness of breath, or yellow skin.

<span class="mw-page-title-main">Breast self-examination</span> Physical and visual inspection of ones own breasts

Breast self-examination (BSE) is a screening method used in an attempt to detect early breast cancer. The method involves the woman herself looking at and feeling each breast for possible lumps, distortions or swelling.

Technetium (<sup>99m</sup>Tc) sestamibi Pharmaceutical drug

Technetium (99mTc) sestamibi (INN) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six (sesta=6) methoxyisobutylisonitrile (MIBI) ligands. The anion is not defined. The generic drug became available late September 2008. A scan of a patient using MIBI is commonly known as a "MIBI scan".

Computed tomography laser mammography (CTLM) is the trademark of Imaging Diagnostic Systems, Inc. for its optical tomographic technique for female breast imaging.

<span class="mw-page-title-main">Prostate biopsy</span> Medical test

Prostate biopsy is a procedure in which small hollow needle-core samples are removed from a man's prostate gland to be examined for the presence of prostate cancer. It is typically performed when the result from a PSA blood test is high. It may also be considered advisable after a digital rectal exam (DRE) finds possible abnormality. PSA screening is controversial as PSA may become elevated due to non-cancerous conditions such as benign prostatic hyperplasia (BPH), by infection, or by manipulation of the prostate during surgery or catheterization. Additionally many prostate cancers detected by screening develop so slowly that they would not cause problems during a man's lifetime, making the complications due to treatment unnecessary.

Prostate cancer screening is the screening process used to detect undiagnosed prostate cancer in men without signs or symptoms. When abnormal prostate tissue or cancer is found early, it may be easier to treat and cure, but it is unclear if early detection reduces mortality rates.

Ductal carcinoma <i>in situ</i> Pre-cancerous breast lesion

Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive cancerous lesion of the breast. DCIS is classified as Stage 0. It rarely produces symptoms or a breast lump that can be felt, typically being detected through screening mammography. It has been diagnosed in a significant percentage of men.

The Breast Imaging-Reporting and Data System (BI-RADS) is a quality assurance tool originally designed for use with mammography. The system is a collaborative effort of many health groups but is published and trademarked by the American College of Radiology (ACR).

<span class="mw-page-title-main">Lung cancer screening</span> Testing asymptomatic patients for lung cancer

Lung cancer screening refers to cancer screening strategies used to identify early lung cancers before they cause symptoms, at a point where they are more likely to be curable. Lung cancer screening is critically important because of the incidence and prevalence of lung cancer. More than 235,000 new cases of lung cancer are expected in the United States in 2021 with approximately 130,000 deaths expected in 2021. In addition, at the time of diagnosis, 57% of lung cancers are discovered in advanced stages, meaning they are more widespread or aggressive cancers. Because there is a substantially higher probability of long-term survival following treatment of localized (60%) versus advanced stage (6%) lung cancer, lung cancer screening aims to diagnose the disease in the localized stage.

The United States Preventive Services Task Force (USPSTF) is "an independent panel of experts in primary care and prevention that systematically reviews the evidence of effectiveness and develops recommendations for clinical preventive services". The task force, a volunteer panel of primary care clinicians with methodology experience including epidemiology, biostatistics, health services research, decision sciences, and health economics, is funded, staffed, and appointed by the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality.

<span class="mw-page-title-main">Breast cancer screening</span> Medical screening of asymptomatic, healthy women for breast cancer

Breast cancer screening is the medical screening of asymptomatic, apparently healthy women for breast cancer in an attempt to achieve an earlier diagnosis. The assumption is that early detection will improve outcomes. A number of screening tests have been employed, including clinical and self breast exams, mammography, genetic screening, ultrasound, and magnetic resonance imaging.

<span class="mw-page-title-main">Molecular breast imaging</span>

Molecular breast imaging (MBI), also known as scintimammography, is a type of breast imaging test that is used to detect cancer cells in breast tissue of individuals who have had abnormal mammograms, especially for those who have dense breast tissue, post-operative scar tissue or breast implants.

Daniel B. Kopans, MD, FACR is a radiologist specializing in mammography and other forms of breast imaging.

<span class="mw-page-title-main">Cancer screening</span> Method to detect cancer

The objective of cancer screening is to detect cancer before symptoms appear, involving various methods such as blood tests, urine tests, DNA tests, and medical imaging. The purpose of screening is early cancer detection, to make the cancer easier to treat and extending life expectancy. In 2019, cancer was the second leading cause of death globally; more recent data is pending due to the COVID-19 pandemic.

Thomas M. Kolb is an American radiologist specializing in the detection and diagnosis of breast cancer in young, predominantly high-risk premenopausal women. He has served as an assistant clinical professor of Radiology at Columbia University College of Physicians and Surgeons from 1994–2010. Kolb is double board certified, having received his training in pediatrics at the Albert Einstein College of Medicine in Bronx, New York, and in diagnostic radiology at the Columbia-Presbyterian Medical Center in New York.

<span class="mw-page-title-main">Triple test score</span>

The triple test score is a diagnostic tool for examining potentially cancerous breasts. Diagnostic accuracy of the triple test score is nearly 100%. Scoring includes using the procedures of physical examination, mammography and needle biopsy. If the results of a triple test score are greater than five, an excisional biopsy is indicated.

Dynamic angiothermography (DATG) is a technique for the diagnosis of breast cancer. This technique, though springing from the previous conception of thermography, is based on a completely different principle. DATG records the temperature variations linked to the vascular changes in the breast due to angiogenesis. The presence, change, and growth of tumors and lesions in breast tissue change the vascular network in the breast. Consequently, through measuring the vascular structure over time, DATG effectively monitors the change in breast tissue due to tumors and lesions. It is currently used in combination with other techniques for diagnosis of breast cancer. This diagnostic method is a low-cost one compared with other techniques.

The Canadian National Breast Screening Study, sometimes abbreviated as CNBSS or NBSS, was a randomized trial conducted with the aim of evaluating whether mammography reduced breast cancer incidence or mortality among women who underwent screening. The trial was initiated in 1980, and was conducted in fifteen screening centers in six different Canadian provinces. It was the first study designed to determine whether mammography was effective among women between the ages of 40 and 49.

<span class="mw-page-title-main">Breast imaging</span>

In medicine, breast imaging is a sub-speciality of diagnostic radiology that involves imaging of the breasts for screening or diagnostic purposes. There are various methods of breast imaging using a variety of technologies as described in detail below. Traditional screening and diagnostic mammography uses x-ray technology and has been the mainstay of breast imaging for many decades. Breast tomosynthesis is a relatively new digital x-ray mammography technique that produces multiple image slices of the breast similar to, but distinct from, computed tomography (CT). Xeromammography and galactography are somewhat outdated technologies that also use x-ray technology and are now used infrequently in the detection of breast cancer. Breast ultrasound is another technology employed in diagnosis and screening that can help differentiate between fluid filled and solid lesions, an important factor to determine if a lesion may be cancerous. Breast MRI is a technology typically reserved for high-risk patients and patients recently diagnosed with breast cancer. Lastly, scintimammography is used in a subgroup of patients who have abnormal mammograms or whose screening is not reliable on the basis of using traditional mammography or ultrasound.

Dense breast tissue, also known as dense breasts, is a condition of the breasts where a higher proportion of the breasts are made up of glandular tissue and fibrous tissue than fatty tissue. Around 40–50% of women have dense breast tissue and one of the main medical components of the condition is that mammograms are unable to differentiate tumorous tissue from the surrounding dense tissue. This increases the risk of late diagnosis of breast cancer in women with dense breast tissue. Additionally, women with such tissue have a higher likelihood of developing breast cancer in general, though the reasons for this are poorly understood.

References

  1. ↑ "Draft Recommendation: Breast Cancer: Screening | United States Preventive Services Taskforce". www.uspreventiveservicestaskforce.org. Retrieved 2024-02-01.
  2. ↑ US Preventive Services Task Force, Nicholson WK, Silverstein M, Wong JB, Barry MJ, Chelmow D, Coker TR, Davis EM, Jaén CR, Krousel-Wood M, Lee S, Li L, Mangione CM, Rao G, Ruiz JM (2024-04-30). "Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement". JAMA. doi:10.1001/jama.2024.5534. ISSN   0098-7484.
  3. ↑ "Breast Cancer Early Detection". cancer.org. 2013-09-17. Archived from the original on 10 August 2014. Retrieved 29 July 2014.
  4. 1 2 Tonelli M, Connor Gorber S, Joffres M, Dickinson J, Singh H, Lewin G, et al. (Canadian Task Force on Preventive Health Care) (November 2011). "Recommendations on screening for breast cancer in average-risk women aged 40–74 years". CMAJ. 183 (17): 1991–2001. doi:10.1503/cmaj.110334. PMC   3225421 . PMID   22106103.
  5. ↑ "Cancer screening: Breast". European Cancer Observatory. Archived from the original on 2012-02-11.
  6. ↑ "Final Recommendation Statement: Breast Cancer: Screening". US Preventive Services Task Force. January 2016. Archived from the original on 13 May 2017. Retrieved 31 May 2017.
  7. ↑ Friedenson B (March 2000). "Is mammography indicated for women with defective BRCA genes? Implications of recent scientific advances for the diagnosis, treatment, and prevention of hereditary breast cancer". MedGenMed. 2 (1): E9. PMID   11104455. Archived from the original on 2001-11-21.
  8. ↑ American Society of Plastic Surgeons (24 April 2014), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation , American Society of Plastic Surgeons, archived from the original on 19 July 2014, retrieved 25 July 2014
  9. 1 2 3 4 "Digital Mammography – Mammography – Imaginis – The Women's Health & Wellness Resource Network". www.imaginis.com. Archived from the original on 30 January 2012. Retrieved 4 May 2018.
  10. ↑ "Mammography (Mammogram)". Radiological Society of North America (RSNA) and American College of Radiology. Archived from the original on 25 January 2018. Retrieved 4 May 2018.
  11. ↑ "How To Perform An Ultrasound-Guided Breast Biopsy". www.theradiologyblog.com. Archived from the original on 18 February 2018. Retrieved 4 May 2018.
  12. ↑ "Radiology – Weill Cornell Medicine". weillcornell.org. Archived from the original on 22 December 2017. Retrieved 4 May 2018.
  13. 1 2 3 Sulik G (2010). Pink Ribbon Blues: How Breast Cancer Culture Undermines Women's Health . New York: Oxford University Press. pp.  193–195. ISBN   978-0-19-974045-1. OCLC   535493589.
  14. ↑ "USPSTF recommendations on Screening for Breast Cancer". Archived from the original on 2013-01-02. Retrieved 2010-09-13.
  15. ↑ "NASA Spinoffs" (PDF). National Aeronautics and Space Administration. Archived (PDF) from the original on 2010-11-25. Retrieved 2010-12-20.
  16. ↑ Hodgson R, Heywang-Köbrunner SH, Harvey SC, Edwards M, Shaikh J, Arber M, Glanville J (June 2016). "Systematic review of 3D mammography for breast cancer screening". Breast. 27: 52–61. doi: 10.1016/j.breast.2016.01.002 . PMID   27212700.
  17. ↑ Gilbert FJ, Tucker L, Young KC (February 2016). "Digital breast tomosynthesis (DBT): a review of the evidence for use as a screening tool". Clinical Radiology. 71 (2): 141–150. doi:10.1016/j.crad.2015.11.008. PMID   26707815.
  18. ↑ Melnikow J, Fenton JJ, Whitlock EP, Miglioretti DL, Weyrich MS, Thompson JH, Shah K (February 2016). "Supplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Services Task Force". Annals of Internal Medicine. 164 (4): 268–278. doi:10.7326/M15-1789. PMC   5100826 . PMID   26757021.
  19. ↑ Weigel S, Berkemeyer S, Girnus R, Sommer A, Lenzen H, Heindel W (May 2014). "Digital mammography screening with photon-counting technique: can a high diagnostic performance be realized at low mean glandular dose?". Radiology. 271 (2): 345–355. doi:10.1148/radiol.13131181. PMID   24495234.
  20. ↑ Fredenberg E, Willsher P, Moa E, Dance DR, Young KC, Wallis MG (November 2018). "Measurement of breast-tissue x-ray attenuation by spectral imaging: fresh and fixed normal and malignant tissue". Physics in Medicine and Biology. 63 (23): 235003. arXiv: 2101.02755 . Bibcode:2018PMB....63w5003F. doi:10.1088/1361-6560/aaea83. PMID   30465547. S2CID   53717425.
  21. ↑ Johansson H, von Tiedemann M, Erhard K, Heese H, Ding H, Molloi S, Fredenberg E (July 2017). "Breast-density measurement using photon-counting spectral mammography". Medical Physics. 44 (7): 3579–3593. Bibcode:2017MedPh..44.3579J. doi: 10.1002/mp.12279 . PMC   9560776 . PMID   28421611.
  22. ↑ Ding H, Molloi S (August 2012). "Quantification of breast density with spectral mammography based on a scanned multi-slit photon-counting detector: a feasibility study". Physics in Medicine and Biology. 57 (15): 4719–4738. Bibcode:2012PMB....57.4719D. doi:10.1088/0031-9155/57/15/4719. PMC   3478949 . PMID   22771941.
  23. ↑ "Cancer of the Breast (Female) - Cancer Stat Facts". National Cancer Institute: Surveillance, Epidemiology, and End Results Program.
  24. ↑ (Otto et al)
  25. ↑ Webb ML, Cady B, Michaelson JS, Bush DM, Calvillo KZ, Kopans DB, Smith BL (September 2014). "A failure analysis of invasive breast cancer: most deaths from disease occur in women not regularly screened". Cancer. 120 (18): 2839–2846. doi:10.1002/cncr.28199. PMID   24018987. S2CID   19236625.
  26. ↑ Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MM (October 2015). "Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients". BMJ. 351: h4901. doi:10.1136/bmj.h4901. PMC   4595560 . PMID   26442924.
  27. ↑ Bleyer A, Baines C, Miller AB (April 2016). "Impact of screening mammography on breast cancer mortality". Int J Cancer. 138 (8): 2003–2012. doi: 10.1002/ijc.29925 . PMID   26562826. S2CID   9538123.
  28. 1 2 3 4 Ray KM, Joe BN, Freimanis RI, Sickles EA, Hendrick RE (February 2018). "Screening Mammography in Women 40-49 Years Old: Current Evidence". AJR. American Journal of Roentgenology. 210 (2): 264–270. doi:10.2214/AJR.17.18707. PMID   29064760.
  29. ↑ "American Cancer Society Guidelines for the Early Detection of Cancer". Archived from the original on 2011-06-13. Retrieved 2011-06-16.
  30. ↑ Lee CH, Dershaw DD, Kopans D, Evans P, Monsees B, Monticciolo D, et al. (January 2010). "Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer". Journal of the American College of Radiology. 7 (1): 18–27. doi:10.1016/j.jacr.2009.09.022. PMID   20129267. S2CID   31652981.
  31. ↑ "Annual Mammograms Now Recommended for Women Beginning at Age 40". American Congress of Obstetricians and Gynecologists. Archived from the original on 2013-09-04. Retrieved 2013-09-11.
  32. ↑ "Screening Mammograms: Questions and Answers". National Cancer Institute. May 2006. Archived from the original on 2007-04-15. Retrieved April 9, 2007.
  33. ↑ "Draft Recommendation: Breast Cancer: Screening | United States Preventive Services Taskforce". www.uspreventiveservicestaskforce.org. Retrieved 2024-01-18.
  34. ↑ Qaseem A, Snow V, Sherif K, Aronson M, Weiss KB, Owens DK (April 2007). "Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians". Annals of Internal Medicine. 146 (7): 511–515. doi:10.7326/0003-4819-146-7-200704030-00007. PMID   17404353. S2CID   9396768.
  35. 1 2 "ACS Breast Cancer Screening Guidelines". www.cancer.org. Retrieved 2024-01-18.
  36. ↑ "Risk Factors for Early Breast Cancer | Bring Your Brave | CDC". www.cdc.gov. 2023-04-13. Retrieved 2024-01-18.
  37. ↑ Monticciolo DL, Newell MS, Moy L, Niell B, Monsees B, Sickles EA (March 2018). "Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR". Journal of the American College of Radiology. 15 (3 Pt A): 408–414. doi:10.1016/j.jacr.2017.11.034. PMID   29371086.
  38. ↑ Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, et al. (April 2020). "NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020". Journal of the National Comprehensive Cancer Network. 18 (4): 380–391. doi:10.6004/jnccn.2020.0017. PMID   32259785.
  39. 1 2 Feig SA, Hendrick RE (1997–2001). "Radiation risk from screening mammography of women aged 40-49 years". Journal of the National Cancer Institute. Monographs. 1997 (22): 119–124. doi:10.1093/jncimono/1997.22.119. PMID   9709287.
  40. ↑ Feig SA, Hendrick RE (1997). "Radiation risk from screening mammography of women aged 40-49 years". Journal of the National Cancer Institute. Monographs. 1997 (22): 119–124. doi:10.1093/jncimono/1997.22.119. PMID   9709287.
  41. ↑ Armstrong K, Moye E, Williams S, Berlin JA, Reynolds EE (April 2007). "Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians". Annals of Internal Medicine. 146 (7): 516–526. doi:10.7326/0003-4819-146-7-200704030-00008. PMID   17404354. S2CID   35208653.
  42. ↑ Whelehan P, Evans A, Wells M, Macgillivray S (August 2013). "The effect of mammography pain on repeat participation in breast cancer screening: a systematic review". Breast. 22 (4): 389–394. doi:10.1016/j.breast.2013.03.003. PMID   23541681.
  43. ↑ Miller D, Livingstone V, Herbison P (January 2008). "Interventions for relieving the pain and discomfort of screening mammography". The Cochrane Database of Systematic Reviews. 2009 (1): CD002942. doi:10.1002/14651858.cd002942.pub2. PMC   8989268 . PMID   18254010.
  44. ↑ Serwan E, Matthews D, Davies J, Chau M (September 2020). "Mammographic compression practices of force- and pressure-standardisation protocol: A scoping review". Journal of Medical Radiation Sciences. 67 (3): 233–242. doi: 10.1002/jmrs.400 . PMC   7476195 . PMID   32420700.
  45. ↑ "Clinical Artefacts" (PDF). International Atomic Energy Agency (IAEA). Archived from the original (PDF) on 29 August 2017. Retrieved 8 March 2022.
  46. ↑ "Mammography Quality Scorecard". U.S. Food and Drug Administration . March 1, 2010. Archived from the original on 2007-04-03. Retrieved March 31, 2010.
  47. ↑ "Mammography Frequently Asked Questions". American College of Radiology . January 8, 2007. Archived from the original on 2007-09-28. Retrieved April 9, 2007.
  48. 1 2 3 4 Taylor P, Potts HW (April 2008). "Computer aids and human second reading as interventions in screening mammography: two systematic reviews to compare effects on cancer detection and recall rate" (PDF). European Journal of Cancer. 44 (6): 798–807. doi:10.1016/j.ejca.2008.02.016. PMID   18353630.
  49. ↑ Taylor CG, Champness J, Reddy M, Taylor P, Potts HW, Given-Wilson R (September 2003). "Reproducibility of prompts in computer-aided detection (CAD) of breast cancer". Clinical Radiology. 58 (9): 733–738. doi:10.1016/S0009-9260(03)00231-9. PMID   12943648.
  50. ↑ Gilbert FJ, Astley SM, Gillan MG, Agbaje OF, Wallis MG, James J, et al. (October 2008). "Single reading with computer-aided detection for screening mammography". The New England Journal of Medicine. 359 (16): 1675–1684. doi: 10.1056/nejmoa0803545 . PMID   18832239.
  51. ↑ Magny SJ, Shikhman R, Keppke AL (January 2024). "Breast Imaging Reporting and Data System". PMID   29083600.{{cite journal}}: Cite journal requires |journal= (help)
  52. ↑ Rao AA, Feneis J, Lalonde C, Ojeda-Fournier H (May 2016). "A Pictorial Review of Changes in the BI-RADS Fifth Edition". Radiographics. 36 (3): 623–639. doi:10.1148/rg.2016150178. PMID   27082663.
  53. ↑ Magny SJ, Shikhman R, Keppke AL (2024). "Breast Imaging Reporting and Data System". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID   29083600 . Retrieved 2024-01-24.
  54. ↑ Lord SJ, Lei W, Craft P, Cawson JN, Morris I, Walleser S, et al. (September 2007). "A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer". European Journal of Cancer. 43 (13): 1905–1917. doi:10.1016/j.ejca.2007.06.007. PMID   17681781.
  55. ↑ Dahlstrom JE, Jain S, Sutton T, Sutton S (May 1996). "Diagnostic accuracy of stereotactic core biopsy in a mammographic breast cancer screening programme". Histopathology. 28 (5): 421–427. doi:10.1046/j.1365-2559.1996.332376.x. PMID   8735717. S2CID   7707679.
  56. ↑ Liu J, Page D, Nassif H, Shavlik J, Peissig P, McCarty C, et al. (2013). "Genetic variants improve breast cancer risk prediction on mammograms". AMIA ... Annual Symposium Proceedings. AMIA Symposium. 2013: 876–885. PMC   3900221 . PMID   24551380.
  57. ↑ Nass SJ, Henderson IC, et al. (Institute of Medicine (U.S.). Committee on Technologies for the Early Detection of Breast Cancer) (2001). Mammography and beyond: developing technologies for the early detection of breast cancer . National Academies Press. ISBN   978-0-309-07283-0.
  58. 1 2 Ingram A. "Breast Cancer Pioneer - Was the First Person to Use X-rays to Study Breast Cancer". Science Heroes. Archived from the original on February 15, 2020. Retrieved March 22, 2011.
  59. ↑ Thomas A (2005). Classic papers in modern diagnostic radiology. Berlin: Springer. p. 540. ISBN   3-540-21927-7.
  60. ↑ Warren SL (1930). "A Roentgenologic Study of the Breast". The American Journal of Roentgenology and Radium Therapy. 24: 113–124.
  61. 1 2 Gold RH (2005). "History of Breast Imaging". In Bassett LW, Jackson VP, Fu KL, Fu YS (eds.). Diagnosis of Diseases of the Breast. Philadelphia, Pennsylvania: Saunders. p. 3. ISBN   978-0-7216-9563-1. OCLC   488959603.
  62. ↑ "History of Cancer Detection 1851–1995". Emory University . Retrieved March 12, 2011.
  63. 1 2 Gardner, Kirsten E. Early Detection: Women, Cancer, and Awareness Campaigns in the Twentieth-Century United States. U of North Carolina P, 2006. p.179
  64. 1 2 Kalaf JM (Jul–Aug 2014). "Mamografia: uma história de sucesso e de entusiasmo científico". Radiologia Brasileira (in Portuguese). 47 (4): VII–VIII. doi:10.1590/0100-3984.2014.47.4e2. ISSN   1678-7099. PMC   4337127 . PMID   25741098.
  65. ↑ Gold RH, Bassett LW, Widoff BE (November 1990). "Highlights from the history of mammography". Radiographics. 10 (6): 1111–1131. doi:10.1148/radiographics.10.6.2259767. PMID   2259767.
  66. ↑ Medich DC, Martel C. Medical Health Physics. Health Physics Society 2006 Summer School. Medical Physics Publishing. ISBN   1930524315 pp.25
  67. ↑ Skloot R (April 2001). "Taboo Organ" (PDF). University of Pittsburgh School of Medicine. 3 (2). Archived (PDF) from the original on 2016-03-03.
  68. ↑ Lerner BH (2003). ""To see today with the eyes of tomorrow": A history of screening mammography". Canadian Bulletin of Medical History. 20 (2): 299–321. doi: 10.3138/cbmh.20.2.299 . PMID   14723235. S2CID   2080082.
  69. ↑ Shapiro S, Strax P, Venet L (February 1966). "Evaluation of periodic breast cancer screening with mammography. Methodology and early observations". JAMA. 195 (9): 731–738. doi:10.1001/jama.1966.03100090065016. PMID   5951878.
  70. ↑ Biller-Andorno N, Jüni P (May 2014). "Abolishing mammography screening programs? A view from the Swiss Medical Board" (PDF). The New England Journal of Medicine. 370 (21): 1965–1967. doi:10.1056/NEJMp1401875. PMID   24738641.
  71. ↑ Kolata G (11 February 2014). "Vast Study Casts Doubts on Value of Mammograms". The New York Times . Archived from the original on 30 May 2014. Retrieved 28 May 2014.
  72. ↑ Pace LE, Keating NL (April 2014). "A systematic assessment of benefits and risks to guide breast cancer screening decisions". JAMA. 311 (13): 1327–1335. doi:10.1001/jama.2014.1398. PMID   24691608.
  73. ↑ Mulcahy N (April 2, 2009). "Screening Mammography Benefits and Harms in Spotlight Again". Medscape. Archived from the original on April 13, 2015.
  74. 1 2 3 Gøtzsche PC, Jørgensen KJ (June 2013). "Screening for breast cancer with mammography". The Cochrane Database of Systematic Reviews. 2013 (6): CD001877. doi:10.1002/14651858.CD001877.pub5. PMC   6464778 . PMID   23737396.
  75. 1 2 3 "Mammography-leaflet; Screening for breast cancer with mammography" (PDF). Archived from the original (PDF) on 2012-09-05. Retrieved 2012-06-24.
  76. ↑ Newman DH (2008). Hippocrates' Shadow. Scibner. p. 193. ISBN   978-1-4165-5153-9.
  77. ↑ Herdman R, Norton L, et al. (Institute of Medicine (US) Committee on New Approaches to Early Detection and Diagnosis of Breast Cancer) (4 May 2018). "Wrap-Up Session". National Academies Press (US). Archived from the original on 4 May 2018. Retrieved 4 May 2018– via www.ncbi.nlm.nih.gov.
  78. ↑ "Mammograms". National Cancer Institute. Archived from the original on 2014-12-17.
  79. 1 2 3 4 Welch HG, Frankel BA (December 12, 2011). "Likelihood that a woman with screen-detected breast cancer has had her "life saved" by that screening". Archives of Internal Medicine. 171 (22): 2043–2046. doi:10.1001/archinternmed.2011.476. PMID   22025097.
     •Lay summary: Parker-Pope T (October 24, 2011). "Mammogram's Role as Savior Is Tested". The New York Times (blog). Archived from the original on 2011-10-27. Retrieved 2011-10-28.
  80. ↑ Nassif H, Page D, Ayvaci M, Shavlik J, Burnside ES (2010). "Uncovering age-specific invasive and DCIS breast cancer rules using inductive logic programming". Proceedings of the ACM international conference on Health informatics - IHI '10. pp. 76–82. doi:10.1145/1882992.1883005. ISBN   978-1-4503-0030-8. S2CID   2112731.
  81. ↑ Ayvaci MU, Alagoz O, Chhatwal J, Munoz del Rio A, Sickles EA, Nassif H, et al. (August 2014). "Predicting invasive breast cancer versus DCIS in different age groups". BMC Cancer. 14 (1): 584. doi: 10.1186/1471-2407-14-584 . PMC   4138370 . PMID   25112586.
  82. ↑ Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L (February 2016). "Effectiveness of Breast Cancer Screening: Systematic Review and Meta-analysis to Update the 2009 U.S. Preventive Services Task Force Recommendation". Annals of Internal Medicine. 164 (4): 244–255. doi: 10.7326/M15-0969 . PMID   26756588.
  83. ↑ Brewer NT, Salz T, Lillie SE (April 2007). "Systematic review: the long-term effects of false-positive mammograms". Annals of Internal Medicine. 146 (7): 502–510. doi:10.7326/0003-4819-146-7-200704030-00006. PMID   17404352. S2CID   22260624.
  84. ↑ de Gelder R, Heijnsdijk EA, van Ravesteyn NT, Fracheboud J, Draisma G, de Koning HJ (27 June 2011). "Interpreting overdiagnosis estimates in population-based mammography screening". Epidemiologic Reviews. 33 (1): 111–121. doi:10.1093/epirev/mxr009. PMC   3132806 . PMID   21709144.
  85. ↑ Jørgensen KJ, Gøtzsche PC (July 2009). "Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends". BMJ. 339: b2587. doi:10.1136/bmj.b2587. PMC   2714679 . PMID   19589821.
  86. ↑ Independent UK Panel on Breast Cancer Screening (November 2012). "The benefits and harms of breast cancer screening: an independent review". Lancet. 380 (9855): 1778–1786. doi:10.1016/S0140-6736(12)61611-0. hdl: 20.500.11820/ed6e2e58-5cfa-4fee-8dc8-641ab03effb8 . PMID   23117178. S2CID   6857671.
  87. ↑ Flemban AF (March 2023). "Overdiagnosis Due to Screening Mammography for Breast Cancer among Women Aged 40 Years and Over: A Systematic Review and Meta-Analysis". Journal of Personalized Medicine. 13 (3): 523. doi: 10.3390/jpm13030523 . PMC   10051653 . PMID   36983705.
  88. ↑ Epstein SS (1979). The politics of cancer. A Doubleday Anchor book (rev. and expand. ed.). Garden City, NY: Anchor Pr. ISBN   978-0-385-15167-2.
  89. ↑ Sickles EA (May 1991). "Periodic mammographic follow-up of probably benign lesions: results in 3,184 consecutive cases". Radiology. 179 (2): 463–468. doi:10.1148/radiology.179.2.2014293. PMID   2014293.
  90. ↑ Allaire BT, Ekwueme DU, Poehler D, Thomas CC, Guy GP, Subramanian S, Trogdon JG (July 2017). "Breast cancer treatment costs in younger, privately insured women". Breast Cancer Research and Treatment. 164 (2): 429–436. doi:10.1007/s10549-017-4249-x. PMC   6083444 . PMID   28432514.
  91. ↑ Ghorbani S, Rezapour A, Eisavi M, Barahman M, Bagheri Faradonbeh S (2023-02-10). "Cost-benefit Analysis of Breast Cancer Screening with Digital Mammography: A Systematic Review". Medical Journal of the Islamic Republic of Iran. 37 (1): 89. doi:10.47176/mjiri.37.89. PMC   10518066 . PMID   37750094.
  92. ↑ Woloshin S, Jørgensen KJ, Hwang S, Welch HG (September 2023). "The New USPSTF Mammography Recommendations - A Dissenting View". The New England Journal of Medicine. 389 (12): 1061–1064. doi:10.1056/NEJMp2307229. PMID   37721382. S2CID   262035301.
  93. ↑ Gøtzsche PC, Jørgensen KJ, et al. (Cochrane Breast Cancer Group) (June 2013). "Screening for breast cancer with mammography". The Cochrane Database of Systematic Reviews. 2013 (6): CD001877. doi:10.1002/14651858.CD001877.pub5. PMC   6464778 . PMID   23737396.
  94. ↑ Trentham-Dietz A, Chapman CH, Jayasekera J (May 2023). "Breast Cancer Screening With Mammography: An Updated Decision Analysis for the U.S. Preventive Services Task Force". AHRQ Publication (23-05303-EF-2).
  95. ↑ Hendrick RE, Helvie MA (February 2011). "United States Preventive Services Task Force screening mammography recommendations: science ignored". AJR. American Journal of Roentgenology. 196 (2): W112–W116. doi:10.2214/AJR.10.5609. PMID   21257850.
  96. ↑ Hellquist BN, Duffy SW, Abdsaleh S, Björneld L, Bordás P, Tabár L, et al. (February 2011). "Effectiveness of population-based service screening with mammography for women ages 40 to 49 years: evaluation of the Swedish Mammography Screening in Young Women (SCRY) cohort". Cancer. 117 (4): 714–722. doi:10.1002/cncr.25650. PMID   20882563. S2CID   42253031.
  97. ↑ "Tabar et al". Radiology.
  98. ↑ "Cultural and language barriers need to be addressed for British-Pakistani women to benefit fully from breast screening". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 2020-09-15. doi:10.3310/alert_41135. S2CID   241324844.
  99. ↑ Woof VG, Ruane H, Ulph F, French DP, Qureshi N, Khan N, et al. (September 2020). "Engagement barriers and service inequities in the NHS Breast Screening Programme: Views from British-Pakistani women". Journal of Medical Screening. 27 (3): 130–137. doi:10.1177/0969141319887405. PMC   7645618 . PMID   31791172.
  100. ↑ Woof VG, Ruane H, French DP, Ulph F, Qureshi N, Khan N, et al. (May 2020). "The introduction of risk stratified screening into the NHS breast screening Programme: views from British-Pakistani women". BMC Cancer. 20 (1): 452. doi: 10.1186/s12885-020-06959-2 . PMC   7240981 . PMID   32434564.
  101. ↑ "Cancer screening across the world is failing people with mental illness". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 2020-05-19. doi:10.3310/alert_40317. S2CID   243581455.
  102. ↑ Solmi M, Firth J, Miola A, Fornaro M, Frison E, Fusar-Poli P, et al. (January 2020). "Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4 717 839 people". The Lancet. Psychiatry. 7 (1): 52–63. doi:10.1016/S2215-0366(19)30414-6. hdl: 11577/3383784 . PMID   31787585. S2CID   208535709.
  103. ↑ "Breast cancer screening: women with poor mental health are less likely to attend appointments". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 2021-06-21. doi:10.3310/alert_46400. S2CID   241919707.
  104. ↑ Ross E, Maguire A, Donnelly M, Mairs A, Hall C, O'Reilly D (June 2020). "Does poor mental health explain socio-demographic gradients in breast cancer screening uptake? A population-based study". European Journal of Public Health. 30 (3): 396–401. doi: 10.1093/eurpub/ckz220 . PMID   31834366.
  105. ↑ Center for Devices and Radiological Health. "Facility Certification and Inspection (MQSA) – Mammography Safety Notifications". www.fda.gov. Retrieved 2019-04-18.
  106. ↑ "Breast Density and Your Mammogram Report". American Cancer Society . March 8, 2023. Retrieved December 13, 2023.
  107. ↑ "Mammography Quality Standards Act and Program". FDA. December 1, 2023. Retrieved December 13, 2023.
  108. ↑ Schopf CM, Ramwala OA, Lowry KP, Hofvind S, Marinovich ML, Houssami N, et al. (November 2023). "Artificial Intelligence-Driven Mammography-Based Future Breast Cancer Risk Prediction: A Systematic Review". Journal of the American College of Radiology. doi:10.1016/j.jacr.2023.10.018. PMID   37949155. S2CID   265107884.
  109. ↑ Liu J, Lei J, Ou Y, Zhao Y, Tuo X, Zhang B, Shen M (October 2023). "Mammography diagnosis of breast cancer screening through machine learning: a systematic review and meta-analysis". Clinical and Experimental Medicine. 23 (6): 2341–2356. doi:10.1007/s10238-022-00895-0. PMID   36242643. S2CID   252904455.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.